[go: up one dir, main page]

UY29282A1 - Anticuerpos humanizados que reconocen el peptido beta amiloideo - Google Patents

Anticuerpos humanizados que reconocen el peptido beta amiloideo

Info

Publication number
UY29282A1
UY29282A1 UY29282A UY29282A UY29282A1 UY 29282 A1 UY29282 A1 UY 29282A1 UY 29282 A UY29282 A UY 29282A UY 29282 A UY29282 A UY 29282A UY 29282 A1 UY29282 A1 UY 29282A1
Authority
UY
Uruguay
Prior art keywords
humanized antibodies
amyloid peptide
beta amyloid
antibodies recognizing
beta
Prior art date
Application number
UY29282A
Other languages
English (en)
Inventor
Guriq Basi
Jack Steven Jacobson
Original Assignee
Neuralab Ltd
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36588573&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY29282(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neuralab Ltd, Wyeth Corp filed Critical Neuralab Ltd
Publication of UY29282A1 publication Critical patent/UY29282A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La invención brinda métodos y agentes mejorados para el tratamiento de enfermedades asociadas a los depósitos amiloideos de AB(Beta) en el cerebro de un paciente. Los agentes preferidos incluyen anticuerpos, Ej., anticuerpos humanizados.
UY29282A 2004-12-15 2005-12-20 Anticuerpos humanizados que reconocen el peptido beta amiloideo UY29282A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63668404P 2004-12-15 2004-12-15

Publications (1)

Publication Number Publication Date
UY29282A1 true UY29282A1 (es) 2006-06-30

Family

ID=36588573

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29282A UY29282A1 (es) 2004-12-15 2005-12-20 Anticuerpos humanizados que reconocen el peptido beta amiloideo

Country Status (8)

Country Link
US (1) US7625560B2 (es)
EP (1) EP1838854B1 (es)
AR (1) AR051528A1 (es)
ES (1) ES2396555T3 (es)
PE (1) PE20061152A1 (es)
TW (1) TW200636066A (es)
UY (1) UY29282A1 (es)
WO (1) WO2006066049A2 (es)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
MXPA05008156A (es) * 2003-02-01 2005-09-30 Neuralab Ltd Inmunizacion activa para generar anticuerpos para beta-a soluble.
TWI374893B (en) * 2003-05-30 2012-10-21 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
EP1668369B1 (en) * 2003-08-20 2016-01-06 ProMIS Neurosciences Inc. Epitope protection assay and method for detecting protein conformations
KR20070073885A (ko) * 2004-10-05 2007-07-10 뉴랄랩 리미티드 재조합 단백질 생산을 향상시키는 방법 및 조성물
EP1838348B1 (en) 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanized amyloid beta antibodies for use in improving cognition
ES2396555T3 (es) 2004-12-15 2013-02-22 Janssen Alzheimer Immunotherapy Anticuerpos que reconocen péptido beta amiloide
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
EP2388274A1 (en) 2005-06-17 2011-11-23 Janssen Alzheimer Immunotherapy Methods of purifying anti A Beta antibodies
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
PL1976877T5 (pl) * 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
AU2014277712B2 (en) * 2005-11-30 2017-07-13 AbbVie Deutschland GmbH & Co. KG Monoclonal antibodies against amyloid beta protein and uses thereof
CN101325972B (zh) * 2005-12-12 2020-06-16 Ac免疫有限公司 具有治疗性质的Aβ1-42特异性单克隆抗体
WO2007068412A2 (en) * 2005-12-12 2007-06-21 Ac Immune Sa A beta 1-42 specific monoclonal antibodies with therapeutic properties
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US7892544B2 (en) 2006-07-14 2011-02-22 Ac Immune Sa Humanized anti-beta-amyloid antibody
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
IL199534A (en) 2007-01-05 2013-01-31 Univ Zuerich An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses.
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
ZA200905537B (en) 2007-03-01 2010-10-27 Probiodrug Ag New use of glutaminyl cyclase inhibitors
DK2142514T3 (da) 2007-04-18 2015-03-23 Probiodrug Ag Thioureaderivater som glutaminylcyclase-inhibitorer
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
SI2182983T1 (sl) 2007-07-27 2014-09-30 Janssen Alzheimer Immunotherapy Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta
WO2009048539A2 (en) 2007-10-05 2009-04-16 Genentech, Inc. Monoclonal antibody
CN101998863B (zh) * 2007-10-05 2015-09-16 基因技术公司 抗淀粉状蛋白β抗体在眼病中的用途
NZ601858A (en) * 2007-10-05 2014-03-28 Genentech Inc Methods and compositions for diagnosis and treatment of amyloidosis
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
DK2949666T3 (en) 2008-12-19 2019-03-25 Biogen Int Neuroscience Gmbh HUMAN ANTI-ALPHA SYNUCLEIN ANTIBODIES
US8614297B2 (en) 2008-12-22 2013-12-24 Hoffmann-La Roche Inc. Anti-idiotype antibody against an antibody against the amyloid β peptide
BR112012008346B1 (pt) 2009-09-11 2021-12-21 Vivoryon Therapeutics N.V. Derivados heterocíclicos, seu processo de preparação, e composição farmacêutica
WO2011109246A1 (en) 2010-03-01 2011-09-09 The J. David Gladstone Institutes Antibody specific for apolipoprotein and methods of use thereof
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
SG183369A1 (en) 2010-03-03 2012-09-27 Boehringer Ingelheim Int Biparatopic abeta binding polypeptides
ES2481823T3 (es) 2010-03-10 2014-07-31 Probiodrug Ag Inhibidores heterocíclicos de glutaminil ciclasa (QC, EC 2.3.2.5)
MX336196B (es) 2010-04-15 2016-01-11 Abbvie Inc Proteinas de union a amiloide beta.
JP5945532B2 (ja) 2010-04-21 2016-07-05 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies
CN105348387B (zh) 2010-08-14 2020-08-25 Abbvie 公司 β淀粉样蛋白结合蛋白
DK2686313T3 (en) 2011-03-16 2016-05-02 Probiodrug Ag Benzimidazole derivatives as inhibitors of glutaminyl cyclase
JP2014514576A (ja) * 2011-04-27 2014-06-19 エイディーライフ インコーポレイティッド アミロイドタンパク質の眼における検出法
AU2012250924B2 (en) 2011-05-02 2017-05-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
PL2723379T3 (pl) 2011-06-23 2019-05-31 Biogen Int Neuroscience Gmbh Cząsteczki wiążące przeciwko alfa-synukleinie
KR20140062469A (ko) 2011-07-20 2014-05-23 젭테온 인코포레이티드 폴리펩티드 분리 방법
JP2015535005A (ja) * 2012-11-06 2015-12-07 メディミューン，エルエルシー 抗シュードモナス属（Ｐｓｅｕｄｏｍｏｎａｓ）ＰｓｌおよびＰｃｒＶ結合分子を用いた併用治療
SG11201509566RA (en) 2013-05-20 2015-12-30 Genentech Inc Anti-transferrin receptor antibodies and methods of use
BR112016018170A2 (pt) * 2014-02-08 2018-02-20 Genentech, Inc. métodos para tratar doença de alzheimer
JP6993228B2 (ja) 2014-11-19 2022-03-03 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体／抗ｂａｃｅ１多重特異性抗体および使用方法
CN107001473B (zh) 2014-11-19 2021-07-09 豪夫迈·罗氏有限公司 抗-运铁蛋白受体抗体及使用方法
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
CA2966365A1 (en) 2014-12-10 2016-06-16 Genentech, Inc. Blood brain barrier receptor antibodies and methods of use
EP3374383A4 (en) * 2015-11-09 2019-05-15 The University Of British Columbia AMYLOID BETA EPITOPES AND ANTIBODIES
CN108350052A (zh) 2015-11-09 2018-07-31 英属哥伦比亚大学 淀粉样蛋白β中间区域中的表位及其构象选择性抗体
WO2017079831A1 (en) 2015-11-09 2017-05-18 The University Of British Columbia N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
CA3031135A1 (en) 2016-07-18 2018-01-25 The University Of British Columbia Antibodies to amyloid beta
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
EP3606964A4 (en) 2017-04-03 2020-12-09 Immunomedics, Inc. SUBCUTANE ADMINISTRATION OF ANTIBODY DRUG CONJUGATES FOR CANCER THERAPY
JP7368856B2 (ja) 2017-07-25 2023-10-25 トゥルーバインディング，インコーポレイテッド Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療
EP4233901A3 (en) 2017-08-22 2023-09-06 Biogen MA Inc. Pharmaceutical compositions containing anti-beta amyloid antibodies
EP3461819B1 (en) 2017-09-29 2020-05-27 Probiodrug AG Inhibitors of glutaminyl cyclase
US20220031867A1 (en) 2018-10-04 2022-02-03 University Of Rochester Glymphatic delivery by manipulating plasma osmolarity
WO2020132230A2 (en) 2018-12-20 2020-06-25 Genentech, Inc. Modified antibody fcs and methods of use
EP3947462A4 (en) * 2019-03-25 2023-01-11 New York University ANTI-GALECTIN-9 ANTIBODIES AND THEIR USES
CA3134785A1 (en) * 2019-03-26 2020-10-01 Janssen Pharmaceutica Nv Antibodies to pyroglutamate amyloid-.beta. and uses thereof
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof

Family Cites Families (294)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5208036A (en) 1985-01-07 1993-05-04 Syntex (U.S.A.) Inc. N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US4713366A (en) 1985-12-04 1987-12-15 The Ohio State University Research Foundation Antigenic modification of polypeptides
US5096706A (en) 1986-03-25 1992-03-17 National Research Development Corporation Antigen-based treatment for adiposity
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JPS62267297A (ja) 1986-05-15 1987-11-19 Tokyo Met Gov Seishin Igaku Sogo Kenkyusho 老人斑反応性モノクロ−ナル抗体、それを産生する細胞株及び該モノクロ−ナル抗体の製造方法
US5278049A (en) 1986-06-03 1994-01-11 Incyte Pharmaceuticals, Inc. Recombinant molecule encoding human protease nexin
US5231170A (en) 1986-08-27 1993-07-27 Paul Averback Antibodies to dense microspheres
US5220013A (en) 1986-11-17 1993-06-15 Scios Nova Inc. DNA sequence useful for the detection of Alzheimer's disease
US5187153A (en) 1986-11-17 1993-02-16 Scios Nova Inc. Methods of treatment using Alzheimer's amyloid polypeptide derivatives
US4879213A (en) 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
DE3702789A1 (de) 1987-01-30 1988-08-18 Bayer Ag Vorlaeuferprotein des apc-polypeptids, dafuer codierende dna und diagnostische verwendung der dna und des proteins
US4912206A (en) 1987-02-26 1990-03-27 The United States Of America As Represented By The Department Of Health And Human Services CDNA clone encoding brain amyloid of alzheimer's disease
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
JPS63245689A (ja) 1987-03-31 1988-10-12 Suntory Ltd ヒトアミロイド関連蛋白モノクロ−ナル抗体
US4883666A (en) 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5583112A (en) 1987-05-29 1996-12-10 Cambridge Biotech Corporation Saponin-antigen conjugates and the use thereof
US5245015A (en) 1991-04-26 1993-09-14 Tanox Biosystems, Inc. Monoclonal antibodies which neutralize HIV-1 through reaction with a conformational epitope in vitro
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5849298A (en) 1987-06-24 1998-12-15 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of bovine myelin
US5641474A (en) 1987-06-24 1997-06-24 Autoimmune, Inc. Prevention of autoimmune diseases by aerosol administration of autoantigens
EP0666080B1 (en) 1987-06-24 2004-01-21 Brigham & Women's Hospital Treatment of autoimmune diseases by oral administration of autoantigens
US5645820A (en) 1987-06-24 1997-07-08 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US5571499A (en) 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US5571500A (en) 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases through administration by inhalation of autoantigens
US5869054A (en) 1987-06-24 1999-02-09 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of autoantigens
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
CA1339014C (en) 1987-10-08 1997-03-25 Ronald E. Majocha Antibodies to a4 amyloid peptide
US5231000A (en) 1987-10-08 1993-07-27 The Mclean Hospital Antibodies to A4 amyloid peptide
JP2518911B2 (ja) 1987-10-23 1996-07-31 森永乳業株式会社 ｃ―ｆｍｓ癌原遺伝子の過剰発現によって特徴づけられた癌の処置用組成物および方法
US5089603A (en) 1989-06-21 1992-02-18 Tanox Biosystems, Inc. Antigenic epitopes present on membrane-bound but not secreted iga
AU3056289A (en) 1988-01-13 1989-08-11 Mclean Hospital Corporation, The Genetic constructs containing the alzheimer brain amyloid gene
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5576184A (en) 1988-09-06 1996-11-19 Xoma Corporation Production of chimeric mouse-human antibodies with specificity to human tumor antigens
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5227159A (en) 1989-01-31 1993-07-13 Miller Richard A Anti-idiotype antibodies reactive with shared idiotopes expressed by B cell lymphomas and autoantibodies
US5262332A (en) 1989-04-05 1993-11-16 Brigham And Women's Hospital Diagnostic method for Alzheimer's disease: examination of non-neural tissue
WO1990012870A1 (en) 1989-04-14 1990-11-01 Research Foundation For Mental Hygiene, Inc. Monoclonal antibody to amyloid peptide
AU5439790A (en) 1989-04-14 1990-11-16 Research Foundation For Mental Hygiene, Inc. Cerebrovascular amyloid protein-specific monoclonal antibody sv17-6e10
AU642693B2 (en) 1989-12-20 1993-10-28 Autoimmune, Inc. Improved treatment of autoimmune diseases by aerosol administration of auto antigens
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
BR9106114A (pt) 1990-03-02 1993-03-09 Autoimmune Inc Metodo para tratar ou prevenir uma doenca auto-imune (ad) e formulacao farmaceutica
EP0451700A1 (en) 1990-04-10 1991-10-16 Miles Inc. Recombinant APP minigenes for expression in transgenic mice as models for Alzheimers's disease
JPH05506990A (ja) 1990-04-24 1993-10-14 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア プロテアーゼ　ネキシン―２の精製、検出、及び使用方法
GB9009548D0 (en) 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
WO1991016819A1 (en) 1990-04-27 1991-11-14 Molecular Rx., Inc. Method and composition for treatment of central nervous systems disease states associated with abnormal amyloid beta protein
US5753624A (en) 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
JPH06507782A (ja) 1990-06-15 1994-09-08 サイオス　ノバ　インコーポレイテッド アルツハイマー病のアミロイド形成開症状を示すヒト以外の組換え哺乳動物
US5780587A (en) 1990-08-24 1998-07-14 President And Fellows Of Harvard College Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
US5702906A (en) 1990-09-25 1997-12-30 Genentech, Inc. Antibodies to neurotrophic factor-4 (NT-4)
AU8768191A (en) 1990-09-28 1992-04-28 Upjohn Company, The Transgenic animals with alzheimer's amyloid precursor gene
KR0140841B1 (ko) 1990-10-15 1998-06-01 조앤 월리스 자기항원의 경구 투여에 의한 자기면역 질병의 치료
DE69233468T3 (de) 1991-01-21 2011-05-05 Elan Pharmaceuticals, Inc., San Francisco Prüfung und modell für alzheimers-krankheit
US5192753A (en) 1991-04-23 1993-03-09 Mcgeer Patrick L Anti-rheumatoid arthritic drugs in the treatment of dementia
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5672805A (en) 1991-07-18 1997-09-30 The Regents Of The University Of California Transgenic mice expressing the neurotoxic C-terminus of β-amyloid precursor protein
JP2966592B2 (ja) 1991-07-20 1999-10-25 萩原 義秀 安定化されたヒトモノクローナル抗体製剤
US5434050A (en) 1991-08-13 1995-07-18 Regents Of The University Of Minnesota Labelled β-amyloid peptide and methods of screening for Alzheimer's disease
US5837268A (en) 1991-10-16 1998-11-17 University Of Saskatchewan GnRH-leukotoxin chimeras
ES2204899T3 (es) 1992-01-07 2004-05-01 Elan Pharmaceuticals, Inc. Modelos de animales transgenicos para la enfermedad de alzheimer.
US5679348A (en) 1992-02-03 1997-10-21 Cedars-Sinai Medical Center Immunotherapy for recurrent HSV infections
KR950700081A (ko) 1992-02-11 1995-01-16 W 로우 죤 이중 캐리어 면역원성 구성물
JP3712260B2 (ja) 1992-02-28 2005-11-02 オートイミューン インク 自己免疫疾患のバイスタンダー抑制
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
EP0561087B1 (en) 1992-03-20 1999-08-04 N.V. Innogenetics S.A. Mutated form of the beta-amyloid precursor protein gene
US5441870A (en) 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
US5604102A (en) 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
US5851787A (en) 1992-04-20 1998-12-22 The General Hospital Corporation Nucleic acid encoding amyloid precursor-like protein and uses thereof
EP0640094A1 (en) 1992-04-24 1995-03-01 The Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
GB9209118D0 (en) 1992-04-28 1992-06-10 Sb 120 Amsterdam Bv Vaccine compositions
AU671649B2 (en) 1992-06-18 1996-09-05 President And Fellows Of Harvard College Diphtheria toxin vaccines
EP0761231B1 (en) 1992-06-25 2000-01-12 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
US6610493B1 (en) 1993-06-17 2003-08-26 Brigham And Women's Hospital Screening compounds for the ability to alter the production of amyloid-β peptide
US5766846A (en) 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US5837672A (en) 1992-07-10 1998-11-17 Athena Neurosciences, Inc. Methods and compositions for the detection of soluble β-amyloid peptide
WO1994001772A1 (en) 1992-07-13 1994-01-20 The Children's Medical Center Corporation SCREEN FOR ALZHEIMER'S DISEASE THERAPEUTICS BASED ON β-AMYLOID PRODUCTION
KR950702635A (ko) 1992-07-31 1995-07-29 크리스틴 헬렌 수덴 감쇠 박테리아에서 재조합 융합 단백질의 발현(Expression of recombinant fusion proteins in attenuated bacteria)
CA2143823C (en) 1992-08-27 2005-07-26 Alfio Comis Retro-, inverso - and retro-inverso synthetic peptide analogues
US5958883A (en) 1992-09-23 1999-09-28 Board Of Regents Of The University Of Washington Office Of Technology Animal models of human amyloidoses
AU5358494A (en) 1992-10-13 1994-05-09 Duke University Method of inhibiting binding of amyloid precursor protein to beta-amyloid protein
US5605811A (en) 1992-10-26 1997-02-25 Athena Neurosciences, Inc. Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein
WO1994010569A1 (en) 1992-10-26 1994-05-11 Schenk Dale B METHODS AND COMPOSITIONS FOR THE DETECTION OF SOLUBLE β-AMYLOID PEPTIDE
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
DE69432629T3 (de) 1993-01-25 2008-01-17 Takeda Pharmaceutical Co. Ltd. Antikörper gegen beta-amyloid oder derivative davon und seine verwendung
US5955317A (en) 1993-01-25 1999-09-21 Takeda Chemical Industries, Ltd. Antibodies to β-amyloids or their derivatives and use thereof
US5358708A (en) 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
DE614989T1 (de) 1993-02-17 1995-09-28 Morphosys Proteinoptimierung Verfahren für in vivo Selektion von Ligandenbindende Proteine.
CA2115900A1 (en) 1993-02-22 1994-08-23 Gerald W. Becker Pharmaceutical screens and antibodies
EP0689551B1 (en) 1993-03-17 2008-02-20 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Immunogenic chimeras comprising nucleic acid sequences encoding endoplasmic reticulum signal sequence peptides and at least one other peptide, and their uses in vaccines and disease treatments
DK0812593T4 (da) 1993-03-23 2008-05-13 Smithkline Beecham Biolog Vaccinepræparater indeholdende 3-O-deacyleret monophosphoryllipid-A
IT1270939B (it) 1993-05-11 1997-05-26 Angeletti P Ist Richerche Bio Procedimento per la preparazione di immunogeni e reagenti diagnostici,e immunogeni e reagenti diagnostici cosi' ottenibili.
AU7043894A (en) 1993-05-28 1994-12-20 Miriam Hospital, The Composition and method for (in vivo) imaging of amyloid deposits
US5464823A (en) 1993-07-20 1995-11-07 The Regents Of The University Of California Mammalian antibiotic peptides
EP0712442B1 (en) 1993-07-30 2002-03-27 Medeva Holdings B.V. Vaccine compositions
WO1995005393A2 (en) 1993-08-18 1995-02-23 Morphosys Gesellschaft Für Proteinoptimierung Mbh Lipopolysaccharide-binding and neutralizing peptides
AU707083B2 (en) 1993-08-26 1999-07-01 Bavarian Nordic Inc. Inducing antibody response against self-proteins with the aid of foreign T-cell epitopes
AU705889B2 (en) 1993-08-26 1999-06-03 Regents Of The University Of California, The Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory peptides
DK96493D0 (da) 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
WO1995006407A1 (en) 1993-08-30 1995-03-09 The Regents Of The University Of California Novel component of amyloid in alzheimer's disease and methods for use of same
ES2236693T3 (es) 1993-09-07 2005-07-16 Smithkline Beecham Corporation Anticuerpos recombinantes contra il4 utiles en el tratamiento de afecciones mediadas por il4.
US5652334A (en) 1993-09-08 1997-07-29 City Of Hope Method for design of substances that enhance memory and improve the quality of life
US5385887A (en) 1993-09-10 1995-01-31 Genetics Institute, Inc. Formulations for delivery of osteogenic proteins
DK0735893T3 (da) 1993-09-14 2009-03-09 Pharmexa Inc PAN DR-bindende peptider til styrkelse af immunsvaret
US5470951A (en) 1993-09-29 1995-11-28 City Of Hope Peptides for antagonizing the effects of amyloid βprotein
US5858981A (en) 1993-09-30 1999-01-12 University Of Pennsylvania Method of inhibiting phagocytosis
EP0728215B1 (en) 1993-10-20 2002-02-20 Duke University METHOD OF BINDING MATERIAL TO THE Beta-AMYLOID PEPTIDE
JP3504963B2 (ja) 1993-10-22 2004-03-08 智靖 羅 抗ヒト高親和性ＩｇＥ受容体モノクローナル抗体に係るアミノ酸配列をコードするＤＮＡ断片
DE69431358T2 (de) 1993-10-22 2003-06-05 Genentech Inc., San Francisco Verfahren und zusammensetzungen zur mikrokapselung von adjuvantien
US5744368A (en) 1993-11-04 1998-04-28 Research Foundation Of State University Of New York Methods for the detection of soluble amyloid β-protein (βAP) or soluble transthyretin (TTR)
JPH07132033A (ja) 1993-11-12 1995-05-23 Hoechst Japan Ltd アルツハイマー病モデルトランスジェニック動物
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5434170A (en) 1993-12-23 1995-07-18 Andrulis Pharmaceuticals Corp. Method for treating neurocognitive disorders
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5877399A (en) 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
EP0742831B1 (en) 1994-01-27 2004-09-29 The Regents Of The University Of Minnesota Transgenic non-human mammals with progressive neurologic disease
US5935927A (en) 1994-02-03 1999-08-10 The Picower Institute For Medical Research Compositions and methods for stimulating amyloid removal in amyloidogenic diseases using advanced glycosylation endproducts
AUPM411994A0 (en) 1994-02-25 1994-03-24 Deakin Research Limited Epitopes
US5795954A (en) 1994-03-04 1998-08-18 Genentech, Inc. Factor VIIa inhibitors from Kunitz domain proteins
US6270757B1 (en) 1994-04-21 2001-08-07 Genetics Institute, Inc. Formulations for IL-11
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
JP3064013B2 (ja) 1994-05-25 2000-07-12 ジョン マクマイケル， 斑形成疾患の治療のための方法及び材料
US5622701A (en) 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
US6417178B1 (en) 1994-07-19 2002-07-09 University Of Pittsburgh Amyloid binding nitrogen-linked compounds for the antemortem diagnosis of alzheimer's disease, in vivo imaging and prevention of amyloid deposits
DE4432382A1 (de) 1994-09-12 1996-03-14 Schaeffler Waelzlager Kg Übertragungselement für eine Getriebeschaltung
US6114133A (en) 1994-11-14 2000-09-05 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
US5589154A (en) 1994-11-22 1996-12-31 Rutgers, The State University Of New Jersey Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease
US5688651A (en) 1994-12-16 1997-11-18 Ramot University Authority For Applied Research And Development Ltd. Prevention of protein aggregation
JP2000510813A (ja) 1995-02-06 2000-08-22 ジェネテイックス・インスティテュート・インコーポレイテッド Ｉｌ−１２用処方
US5786180A (en) 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
US5624937A (en) 1995-03-02 1997-04-29 Eli Lilly And Company Chemical compounds as inhibitors of amyloid beta protein production
WO1996028471A1 (en) 1995-03-14 1996-09-19 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
US6303567B1 (en) 1995-03-14 2001-10-16 Praecis Pharmaceuticals, Inc . Modulators of β-amyloid peptide aggregation comprising D-amino acids
US5817626A (en) 1995-03-14 1998-10-06 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation
US5854215A (en) 1995-03-14 1998-12-29 Praecis Pharmaceuticals Incorporated Modulators of β-amyloid peptide aggregation
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
JPH11508126A (ja) 1995-05-23 1999-07-21 モルフォシス ゲゼルシャフト ファー プロテインオプティマイルング エムベーハー 多量体タンパク質
WO1996039176A1 (en) 1995-06-05 1996-12-12 Brigham & Women's Hospital USE OF ORAL TOLERANCE TO SUPPRESS BOTH Th1 AND Th2 IMMUNE RESPONSES AND TO SUPPRESS ANTIBODY PRODUCTION
ATE214603T1 (de) 1995-06-30 2002-04-15 American Cyanamid Co Stabile makrolide und makrolide imptstoff- zusammensetzungen
EP0846171B1 (en) 1995-07-07 2005-09-21 Darwin Molecular Corporation Chromosome 1 gene and gene products related to alzheimer's disease
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
ATE219517T1 (de) 1995-08-18 2002-07-15 Morphosys Ag Protein-/(poly)peptidbibliotheken
US5824322A (en) 1995-08-21 1998-10-20 Cytrx Corporation Compositions and methods for growth promotion
US5846533A (en) 1995-09-14 1998-12-08 The Regents Of The University Of California Antibodies specific for native PrPSc
US5731284A (en) 1995-09-28 1998-03-24 Amgen Inc. Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product
US5985242A (en) 1995-10-27 1999-11-16 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
US5750361A (en) 1995-11-02 1998-05-12 The Regents Of The University Of California Formation and use of prion protein (PRP) complexes
JP3830525B2 (ja) 1995-11-10 2006-10-04 サイトジェン，コーポレーション 組織横断輸送を強化するペプチドとその同定法および使用法
WO1997021728A1 (en) 1995-12-12 1997-06-19 Karolinska Innovations Ab PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)
JPH09178743A (ja) 1995-12-27 1997-07-11 Oriental Yeast Co Ltd 可溶性ａｐｐの定量法
US6015662A (en) * 1996-01-23 2000-01-18 Abbott Laboratories Reagents for use as calibrators and controls
US5770700A (en) 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
JP2000505306A (ja) 1996-02-26 2000-05-09 モルフォシス・アクチェンゲゼルシャフト ２つまたはそれ以上の相互作用性（ポリ）ペプチドをコードする核酸配列の新規同定方法
US6150091A (en) 1996-03-06 2000-11-21 Baylor College Of Medicine Direct molecular diagnosis of Friedreich ataxia
WO1997035612A1 (fr) 1996-03-23 1997-10-02 The Research Foundation For Microbial Diseases Of Osaka University Antigene a fragment fonctionnel de la toxine du tetanos, et vaccin contre le tetanos
US6284533B1 (en) 1996-05-01 2001-09-04 Avant Immunotherapeutics, Inc. Plasmid-based vaccine for treating atherosclerosis
WO1998002462A1 (en) 1996-07-16 1998-01-22 Morphosys Gesellschaft Für Proteinoptimierung Mbh Immunoglobulin superfamily domains and fragments with increased solubility
CA2183901A1 (en) 1996-08-22 1998-02-23 Johanna E. Bergmann Targets for therapy and diagnosis of alzheimer's disease and down syndrome in humans
WO1998008868A1 (en) 1996-08-27 1998-03-05 Praecis Pharmaceuticals Incorporated MODULATORS OF β-AMYLOID PEPTIDE AGGREGATION COMPRISING D-AMINO ACIDS
US6057367A (en) 1996-08-30 2000-05-02 Duke University Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses
US6797495B2 (en) 1996-11-05 2004-09-28 The Regents Of The University Of California Somatic cells with ablated PrP gene and methods of use
US6022859A (en) 1996-11-15 2000-02-08 Wisconsin Alumni Research Foundation Inhibitors of β-amyloid toxicity
WO1998022120A1 (en) 1996-11-19 1998-05-28 The Wistar Institute Of Anatomy & Biology Diagnostic and therapeutic reagents for alzheimer's disease
US6962984B2 (en) 1996-12-05 2005-11-08 Nihon University IgA nephropathy-related DNA
US6218506B1 (en) 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
US20030068316A1 (en) 1997-02-05 2003-04-10 Klein William L. Anti-ADDL antibodies and uses thereof
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US5798102A (en) 1997-03-04 1998-08-25 Milkhaus Laboratory, Inc. Treatment of cardiomyopathy
NZ337765A (en) 1997-04-09 2001-09-28 Mindset Biopharmaceuticals Usa Recombinant antibodies having specificity for beta-amyloid N-terminus and C-terminus and use in treating Alzheimer's Disease
US20020086847A1 (en) 1997-04-09 2002-07-04 Mindset Biopharmaceuticals (Usa) Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
US6787319B2 (en) 1997-04-16 2004-09-07 American Home Products Corp. β-amyloid peptide-binding proteins and polynucleotides encoding the same
EP1003531B1 (en) 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
DE69810481T2 (de) 1997-06-13 2003-09-25 Genentech Inc., San Francisco Stabilisierte antikörperformulierung
WO1999000150A2 (en) 1997-06-27 1999-01-07 Regents Of The University Of California Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor
IT1293511B1 (it) 1997-07-30 1999-03-01 Gentili Ist Spa Anticorpi monoclonali catalitici ad attivita' proteasica per la lisi selettiva della componente proteica di placche e aggregati correlati
DE69842048D1 (de) 1997-08-01 2011-01-27 Max Planck Gesellschaft Zusammensetzung und verfahren zum nachweis von krankheiten in zusammenhang mit der bildung von amyloid-ähnlichen fibrillen oder protein-aggregaten
JP2002501721A (ja) 1997-08-01 2002-01-22 モルフォシス・アクチェンゲゼルシャフト 多量体（ポリ）ペプチドコンプレックスのメンバーをコードする核酸配列を同定するための新規方法およびファージ
ES2327693T3 (es) 1997-08-29 2009-11-02 Antigenics Inc. Composiciones que comprenden el adyvante qs-21 y polisorbato o ciclodextrina excipiente.
US6175057B1 (en) 1997-10-08 2001-01-16 The Regents Of The University Of California Transgenic mouse model of alzheimer's disease and cerebral amyloid angiopathy
DE69828574T2 (de) 1997-11-14 2005-10-06 Sankyo Co., Ltd. Transgenes Tier als Modell für Allergie und seine Verwendung
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
DE69831971T2 (de) 1997-12-03 2006-07-06 Neuralab Ltd., Flatts Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer
TR200001596T2 (tr) 1997-12-03 2000-12-21 Fujisawa Pharmaceutical Co., Ltd. Yumuşak hap ilaç ve bunun üretim usulü
FR2777015B3 (fr) 1998-02-23 2000-09-15 Financ De Biotechnologie Procede et moyens pour l'obtention de modeles cellulaires et animaux de maladies neurodegeneratives
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US20050059802A1 (en) 1998-04-07 2005-03-17 Neuralab Ltd Prevention and treatment of amyloidogenic disease
US20050059591A1 (en) 1998-04-07 2005-03-17 Neuralab Limited Prevention and treatment of amyloidogenic disease
WO1999055369A1 (en) 1998-04-28 1999-11-04 Smithkline Beecham Corporation Monoclonal antibodies with reduced immunogenicity
NO314086B1 (no) 1998-05-08 2003-01-27 Gemvax As Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til
CA2328612A1 (en) 1998-05-19 1999-11-25 Yeda Research And Development Co., Ltd. Activated t cells, nervous system-specific antigens and their uses
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
KR100701580B1 (ko) 1998-05-21 2007-03-30 유니버시티 오브 테네시 리서치 파운데이션 항-아밀로이드 항체를 이용한 아밀로이드 제거 방법들
US6727349B1 (en) 1998-07-23 2004-04-27 Millennium Pharmaceuticals, Inc. Recombinant anti-CCR2 antibodies and methods of use therefor
IL141868A0 (en) 1998-10-05 2002-03-10 M & E Biotech As Novel methods for therapeutic vaccination
CA2354862A1 (en) 1998-10-19 2000-04-27 Yeda Research And Development Co. Ltd. Treatment of systemic lupus erythematosus by down-regulating the autoimmune response to autoantigens
GB2348203B (en) 1998-11-04 2002-06-19 Imp College Innovations Ltd Solube beta-forms of prion proteins, methods of preparation and use
CA2355894C (en) 1999-01-19 2006-10-10 Pharmacia & Upjohn Company Gamma-irradiation sterilized polyethylene packaging
JP2002535289A (ja) 1999-01-22 2002-10-22 ドウアリング，マシユー・ジヨン 神経疾患のワクチン媒介治療
ATE384077T1 (de) 1999-05-05 2008-02-15 Neurochem Int Ltd Stereoselektive antifibrillogene peptide
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
AR024558A1 (es) 1999-06-01 2002-10-16 Neuralab Ltd Composiciones del peptido a-beta y procesos para producir las mismas
PT1409654E (pt) 1999-06-16 2008-11-25 Boston Biomedical Res Inst Controlo imunológico dos níveis de beta-amilóide in vivo
EP1368486A4 (en) 1999-07-15 2009-04-01 Genetics Inst Llc IL-11 FORMULATIONS
JP4796725B2 (ja) 1999-08-04 2011-10-19 ユニバーシティ オブ サザン カリフォルニア アミロイドβタンパク質（球状アセンブリー及びその使用）
AU784568B2 (en) 1999-09-03 2006-05-04 Ramot At Tel-Aviv University Ltd Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases
US6294171B2 (en) 1999-09-14 2001-09-25 Milkhaus Laboratory, Inc. Methods for treating disease states comprising administration of low levels of antibodies
US20020094335A1 (en) 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
WO2001039796A2 (en) 1999-11-29 2001-06-07 Neurochem Inc. Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
WO2001042306A2 (en) 1999-12-08 2001-06-14 Mindset Biopharmaceuticals (Usa), Inc. Chimeric peptides (short b-cell epitope joined to a t-cell epitope) and their use for immunization
US6399314B1 (en) 1999-12-29 2002-06-04 American Cyanamid Company Methods of detection of amyloidogenic proteins
DE60114157T2 (de) 2000-02-21 2006-06-29 Pharmexa A/S Verfahren zur herabregulierung von amyloid
CZ20022748A3 (cs) 2000-02-21 2004-03-17 Pharmexa A/S Nová metoda regulace obsahu amyloidu
SK288711B6 (sk) 2000-02-24 2019-11-05 Univ Washington Humanizovaná protilátka, jej fragment a ich použitie, polynukleová kyselina, expresný vektor, bunka a farmaceutický prostriedok
US7485616B2 (en) 2000-04-05 2009-02-03 University Of Tennessee Research Foundation Methods of investigating, diagnosing, and treating amyloidosis
JP2003534351A (ja) 2000-05-22 2003-11-18 ニュー・ヨーク・ユニヴァーシティー アミロイドβ及びアミロイド沈着物に対する免疫応答誘導のための、アミロイドβと相同的な、合成の、免疫原性だが非アミロイド原性ペプチド
JP5362164B2 (ja) 2000-07-07 2013-12-11 バイオアークティック ニューロサイエンス アーベー アルツハイマー病の予防及び治療
EP1172378A1 (en) 2000-07-12 2002-01-16 Richard Dr. Dodel Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
US20020009445A1 (en) 2000-07-12 2002-01-24 Yansheng Du Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
US20030092145A1 (en) 2000-08-24 2003-05-15 Vic Jira Viral vaccine composition, process, and methods of use
PT1317479E (pt) 2000-09-06 2009-10-29 Univ Pasteur Métodos e composições para doenças associadas à amiloidose
IT1319277B1 (it) 2000-10-24 2003-09-26 Chiesi Farma Spa Proteine di fusione utili per il trattamento di immunizzazione dellamalattia di alzheimer.
IL139308A0 (en) 2000-10-26 2001-11-25 Marikovsky Moshe Peptides from amyloid precursor protein which inhibit tumor growth and metastasis
ATE355374T1 (de) 2000-11-27 2006-03-15 Praecis Pharm Inc Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
WO2002060920A2 (en) 2000-12-27 2002-08-08 Board Of Regents, University Of Texas System Prion isomers, methods of making, methods of using, and compositions and products comprising prion isomers
US20020160394A1 (en) 2001-01-24 2002-10-31 Bayer Corporation Regulation of transthyretin to treat obesity
EP1251138B1 (en) 2001-04-19 2006-07-26 Hermann Dr. Schätzl Prion protein dimers useful for vaccination
WO2002088306A2 (en) 2001-04-30 2002-11-07 Eli Lilly And Company Humanized antibodies
ATE409047T1 (de) 2001-04-30 2008-10-15 Lilly Co Eli Humanisierte antikörper
US6906169B2 (en) 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
US20020197258A1 (en) 2001-06-22 2002-12-26 Ghanbari Hossein A. Compositions and methods for preventing protein aggregation in neurodegenerative diseases
EP1409018B1 (en) 2001-07-25 2010-01-06 Facet Biotech Corporation Stable lyophilized pharmaceutical formulation the igg antibody daclizumab
US20030135035A1 (en) 2001-08-09 2003-07-17 Mark Shannon Human ZZAP1 protein
WO2003015691A2 (en) * 2001-08-17 2003-02-27 Eli Lilly And Company RAPID IMPROVEMENT OF COGNITION IN CONDITIONS RELATED TO A$g(b)
JP2005503789A (ja) 2001-08-17 2005-02-10 イーライ・リリー・アンド・カンパニー 抗Ａβ抗体
US20040241164A1 (en) 2001-08-17 2004-12-02 Bales Kelly Renee Use of antibodies having high affinity for soluble ab to treat conditions and diseases related to ass
US20030082191A1 (en) 2001-08-29 2003-05-01 Poduslo Joseph F. Treatment for central nervous system disorders
US7781413B2 (en) 2001-10-31 2010-08-24 Board Of Regents, The University Of Texas System SEMA3B inhibits tumor growth and induces apoptosis in cancer cells
NZ532896A (en) 2001-11-08 2007-08-31 Pdl Biopharma Inc Stable liquid pharmaceutical formulation of IGG antibodies including daclizumab and fontolizumab
CA2466841A1 (en) 2001-11-21 2003-06-05 New York University Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid .beta., prion protein, amylin, .alpha.-synuclein, or polyglutamine repeats for induction of an immune response thereto
US20050227941A1 (en) 2001-12-17 2005-10-13 Karen Duff Sequestration of ass in the periphery in the absence of immunomodulating agent as a therapeutic approach for the treatment or prevention of beta-amyloid related diseases
AR038568A1 (es) 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
CA2476776A1 (en) 2002-02-21 2003-09-04 Duke University Reagents and treatment methods for autoimmune diseases
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
AU2003250102B2 (en) 2002-07-24 2009-09-17 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
WO2004031400A2 (en) 2002-10-01 2004-04-15 Northwestern University Amyloid beta-derived diffusible ligands (addls), addl-surrogates, addl-binding molecules, and uses thereof
FR2846667B1 (fr) 2002-11-06 2004-12-31 Pasteur Institut Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives
US20040191243A1 (en) 2002-12-13 2004-09-30 Bei Chen System and method for stabilizing antibodies with histidine
MXPA05008156A (es) 2003-02-01 2005-09-30 Neuralab Ltd Inmunizacion activa para generar anticuerpos para beta-a soluble.
DE602004027348D1 (de) 2003-02-10 2010-07-08 Applied Molecular Evolution Abeta-bindende moleküle
DK2335725T3 (en) 2003-04-04 2017-01-23 Genentech Inc Highly concentrated antibody and protein formulations
EP1480041A1 (en) 2003-05-22 2004-11-24 Innogenetics N.V. Method for the prediction, diagnosis and differential diagnosis of Alzheimer's disease
TWI374893B (en) 2003-05-30 2012-10-21 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
WO2005014041A2 (en) 2003-07-24 2005-02-17 Novartis Ag Use of an amyloid beta dna vaccine for the treatment and/or prevention of amyloid diseases
US20060233788A1 (en) * 2003-09-05 2006-10-19 Heiman Mark L Anti-ghrelin antibodies
HUE026000T2 (en) 2003-12-17 2016-04-28 Wyeth Llc Immunogenic peptide-bearing conjugates and methods for their preparation
JP4696079B2 (ja) 2003-12-17 2011-06-08 ヤンセン アルツハイマー イミュノセラピー Ａβ免疫原性ペプチド担体結合物およびそれの製造方法
KR20070073885A (ko) 2004-10-05 2007-07-10 뉴랄랩 리미티드 재조합 단백질 생산을 향상시키는 방법 및 조성물
WO2006047670A2 (en) 2004-10-26 2006-05-04 Wyeth Methods for assessing antibodies to neurodegenerative disease-associated antigens
EP1838349A1 (en) 2004-12-15 2007-10-03 Neuralab, Ltd. Amyloid beta antibodies for use in improving cognition
US20060240486A1 (en) 2004-12-15 2006-10-26 Johnson-Wood Kelly L Immunoprecipitation-based assay for predicting in vivo efficacy of beta-amyloid antibodies
EP1838348B1 (en) 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanized amyloid beta antibodies for use in improving cognition
US20060153772A1 (en) 2004-12-15 2006-07-13 Wyeth Contextual fear conditioning for predicting immunotherapeutic efficacy
ES2396555T3 (es) 2004-12-15 2013-02-22 Janssen Alzheimer Immunotherapy Anticuerpos que reconocen péptido beta amiloide
EP1841456A2 (en) 2005-01-28 2007-10-10 Wyeth Stabilized liquid polypeptide formulations
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
EP2388274A1 (en) 2005-06-17 2011-11-23 Janssen Alzheimer Immunotherapy Methods of purifying anti A Beta antibodies

Also Published As

Publication number Publication date
EP1838854B1 (en) 2012-10-31
WO2006066049A3 (en) 2006-10-05
US7625560B2 (en) 2009-12-01
PE20061152A1 (es) 2006-10-13
ES2396555T3 (es) 2013-02-22
EP1838854A2 (en) 2007-10-03
TW200636066A (en) 2006-10-16
US20060165682A1 (en) 2006-07-27
WO2006066049A2 (en) 2006-06-22
AR051528A1 (es) 2007-01-17

Similar Documents

Publication Publication Date Title
UY29282A1 (es) Anticuerpos humanizados que reconocen el peptido beta amiloideo
UY28337A1 (es) Anticuerpos humanizados que reconocen el peptido beta amiloide
UY27721A1 (es) Anticuerpos humanizados que reconocen el peptido amiloide beta.
UY29284A1 (es) Anticuerpos ab(beta) humanizados usados en mejorar la cognicion
ECSP034685A (es) Anticuerpos humanizados que reconocen el peptido amiloideo beta
CY1110963T1 (el) Εξανθρωπισμενα αντισωματα που αναγνωριζουν πεπτιδιο βητα αμυλοειδους
UY29283A1 (es) Anticuerpos ab(beta)usados en mejorar la cognicion
DOP2006000099A (es) Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos
EA200700083A1 (ru) Антитела, направленные против бета-амилоидного пептида, и способы их применения
CY1112277T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
DOP2006000013A (es) Dosis de anticuerpos en el tratamiento de enfermedades asociadas a las celulas b
BRPI0414513A (pt) kid3 e anticorpos de kid3 que se ligam a ele
AR055072A1 (es) Uso de anticuerpos anti- madcam para el tratamiento de enfermedad celiaca y esprue tropical
CR8883A (es) Anticuerpos dirigidos contra peptido beta-amiloide y procedimientos que usan los mismos
AR034108A1 (es) Terapia de la psoriasis
CY1113459T1 (el) Θεραπεια καταστασεων που περιλαμβανουν απομυελινωση

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20160610